Objective: To analyze the differences in kidney function of Wistar strain rats that received a combination of vitamin E and cisplatin, compared with cisplatin alone. Material & Methods: An experimental prospective study with post-test only control design, using male Wistar strain rats (Rattus norvegicus). Rats were randomized using the simple randomized sampling method. Treatment was given in the form of exposure to cisplatin 5 mg/kg (positive control group), with a combination of vitamin E 100 mg/kg and 200 mg/kg (treatment group), to evaluate its effect on kidney function as measured by blood urea nitrogen (BUN) and creatinine serum. Results: Statistical analysis of Mann Whitney showed that there were no differences in BUN levels in the positive control group (cisplatin 5 mg/kg) against each treatment group (p>0.05). Further analysis showed that there was no significant difference between treatment group 1 (Vitamin E 100 mg/kg) and treatment group 2 (Vitamin E 200 mg/kg). There was no difference in serum creatinine levels in the positive control group compared to a treatment group that received both vitamin E 100 mg/kg and the vitamin E 200 mg/kg (p>0.05). further analysis revealed no significant difference in serum creatinine levels between the group that receives vitamin E 100 mg/kg and 200 mg/kg. Conclusion: Vitamin E at doses of 100 mg/kg and 200 mg/kg did not have the nephroprotective feature in cisplatin-exposed Wistar rats.
Blood urea nitrogen, cisplatin, nephroprotective, serum creatinine, vitamin E
Perše M, Večerić-Haler Ž. Cisplatin-induced rodent model of kidney injury: Characteristics and challenges. Biomed Res Int. 2018.
Rosenberg B, Charles F. Kettring prize. Fundamental studies with cisplatin. Cancer. 1985 May; 55(10): 2303–16.
Darwish MA, Abo-Youssef AM, Khalaf MM, Abo-Saif AA, Saleh IG, Abdelghany TM. Vitamin E mitigates cisplatin-induced nephrotoxicity due to reversal of oxidative/nitrosative stress, suppression of inflammation and reduction of total renal platinum accumulation. J Biochem Mol Toxicol. 2017; 31(1): e21833.
Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol. 2003; 23(5): 460–4.
Arunkumar P, Viswanatha G, Radheshyam N, Mukund H, Belliyappa M. Science behind cisplatin-induced nephrotoxicity in humans: A clinical study. Asian Pac J Trop Biomed. 2012; 2(8): 640–4.
Weijl NI, Wipkink-Bakker A, Lentjes EGWM, Berger HM, Cleton FJ, Osanto S. Cisplatin combination chemotherapy induces a fall in plasma antioxidants of cancer patients. Ann Oncol. 1998; 9(12): 1331–7.
Liu P, Feng Y, Wang Y, Zhou Y, Zhao L. Protective effect of vitamin E against acute kidney injury. Liu F, Lee D-H, Lagoa R, Kumar S, editors. Biomed Mater Eng. 2015; 26(s1): S2133–44.
Zainuddin M. Metodologi Penelitian. Jakarta: Sagung Seto; 1995. 62–66 p.
Dahlan MS. Statistik untuk kedokteran dan kesehatan: uji hipotesis. Jakarta: Bina Mitra Press; 2006.
Manohar S, Leung N. Cisplatin nephrotoxicity : a review of the literature. J Nephrol. 2017.
Kunze D, Erdmann K, Froehner M, Wirth MP, Fuessel S. siRNA-mediated Inhibition of Antiapoptotic Genes Enhances Chemotherapy Efficacy in Bladder Cancer Cells. 2012; 4318: 4313–8.
Ozkok A, Edelstein CL. Pathophysiology of Cisplatin-Induced Acute Kidney Injury. 2014.
Volarevic V, Djokovic B, Jankovic MG, Harrell CR, Fellabaum C, Djonov V, et al. Molecular mechanisms of cisplatin-induced nephrotoxicity : a balance on the knife edge between renoprotection and tumor toxicity. 2019; 9: 1–14.
Tchounwou PB, Dasari S. Cisplatin in cancer therapy : molecular mechanisms of action. 2015; 364–78.
Tsang RY, Al-Fayea T, Au HJ. Cisplatin overdose: Toxicities and management. Drug Saf. 2009; 32(12): 1109–22.
Siddik ZH. Mechanisms of Action of Cancer Chemotherapeutic Agents : DNA-Interactive Alkylating Agents and Antitumour Platinum-Based Drugs. 2002.
Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of Cisplatin Nephrotoxicity. 2010; 2: 2490–518.
Darwish MA, Saleh IG, Abo-youssef AM, Abdelghany TM, Khalaf MM, Abo-saif AA. Vitamin E mitigates cisplatin-induced nephrotoxicity due to reversal of oxidative / nitrosative stress , suppression of inflammation and reduction of total renal platinum accumulation. 2016; 1–9.
Kontush A, Finckh B, Karten B, Kohlschutter A, Beisiegel U. Antioxidant and prooxidant activity of a-tocopherol in human plasma and low density lipoprotein. 1996; 37: 1436–48.
Herrera E, Barbas C. Vitamin E : action , metabolism and perspectives. 2001; 57(1): 43–56.
Pearson P, Lewis SA, Britton J, Young IS, Fogarty A. The Pro-Oxidant Activity of High-Dose Vitamin E Supplements in Vivo. 2006; 20(5): 271–3.
Tafazoli S, Wright JS, Brien PJO. Prooxidant and Antioxidant Activity of Vitamin E Analogues and Troglitazone. 2005; 1567–74.
Rizvi S, Raza ST, Ahmed F, Ahmad A, Abbas S, Mahdi F. The role of vitamin E in Human Health And Some Disease. 2014; 14: 157–65.
Dillioglugil MO, Maral Kir H, Gulkac MD, Özon Kanli A, Ozdogan HK, Acar O, et al. Protective Effects of Increasing Vitamin E and A Doses on Cisplatin-Induced Oxidative Damage to Kidney Tissue in Rats. Urol Int. 2005; 75(4): 340–4.
Yildirim Z. Oral erdosteine administration attenuates cisplatin-induced renal tubular damage in rats. Pharmacol Res. 2003; 47(2): 149–56.
Antunes G, Darin LM, Bianchi J M de LP. Protective Effects Of Vitamin C Against Cisplatin-Induced Nephrotoxicity And Lipid Peroxidation In Adult Rats: A Dose-Dependent Study. Pharmacol Res. 2000; 41(4): 405–11.